Tesamorelin vs Pinealon
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Pinealon
Pinealon is a short synthetic peptide developed from research on the pineal gland. It has shown neuroprotective and cognitive-enhancing properties in animal studies.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Pinealon |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Penetrates cell membranes and interacts with DNA to regulate gene expression related to neuronal survival and function. May support pineal gland function and melatonin production. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Typical dosing: 10-20mg daily, taken in divided doses. Often used in cycles of 10-20 days. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Can be taken orally (capsules) or sublingually. Best absorbed on an empty stomach. Often combined with other neuroprotective peptides. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Generally well-tolerated. Limited reported side effects. May affect sleep patterns initially. |
| Best For |